• Dicoumarol Inhibits IRE1α to Protect Against ER Stress-Induc

  2026-05-24

  This study identifies dicoumarol as a selective IRE1α inhibitor that protects against acute hepatic endoplasmic reticulum (ER) stress and liver injury in mice. The work establishes a platform for drug discovery targeting the unfolded protein response (UPR), with implications for therapeutic strategies in liver disorders driven by ER stress.

• Berberrubine Modulates Lipid Metabolism and Microbiota in NA

  2026-05-23

  Yang et al. (2022) provide direct evidence that berberrubine, a primary metabolite of berberine, alleviates non-alcoholic fatty liver disease by targeting both hepatic lipid/glucose pathways and gut microbiota composition. These findings clarify berberrubine's mechanistic actions and suggest new directions for hepatoprotection agent research.

• Imatinib Hydrochloride: Mechanistic Insights for Targeted Ca

  2026-05-22

  Explore the advanced molecular mechanisms of Imatinib hydrochloride (STI571 hydrochloride) as a tyrosine kinase inhibitor for cancer research. This article offers novel perspectives on conformational dynamics, dual-action inhibition, and assay optimization, extending beyond existing resources.

• Anagliptin (SK-0403): From DPP-4 Inhibition to Vascular Modu

  2026-05-22

  Explore how Anagliptin (SK-0403) transcends DPP-4 inhibition, uniquely modulating vascular tone through Kv channel and SERCA pump activity. This article delivers a critical, evidence-driven guide for researchers investigating diabetes-cardiovascular intersections.

• Sitagliptin Phosphate Monohydrate: Advanced DPP-4 Inhibitor

  2026-05-21

  Sitagliptin phosphate monohydrate empowers metabolic disease research with reliable DPP-4 inhibition, enabling precise modulation of incretin pathways. This article provides evidence-based protocols, troubleshooting insights, and expert guidance for maximizing data quality and reproducibility in both in vitro and in vivo models.

• Canagliflozin Alters Mitochondrial Structure in Diabetic Kid

  2026-05-21

  This study demonstrates that canagliflozin, an SGLT2 inhibitor, promotes structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. These findings suggest that mitochondrial remodeling may underlie the nephroprotective effects of SGLT2 inhibition, with implications for diabetes and kidney disease research.

• Dehydroabietic Acid: Advanced Modulation of PPAR-α/γ in Meta

  2026-05-20

  Explore how Dehydroabietic acid, a dual PPAR-α/γ agonist, enables advanced, mechanism-driven metabolic disorder research. This article reveals deeper scientific insights and recent reference findings that expand practical workflows beyond established protocols.

• Sitagliptin Phosphate Monohydrate: Protocols and Troubleshoo

  2026-05-20

  Sitagliptin phosphate monohydrate empowers metabolic researchers with precision DPP-4 inhibition and reproducible incretin hormone modulation. This guide details workflow enhancements, protocol parameters, and troubleshooting strategies to maximize experimental success in type II diabetes and metabolic disease models.

• (+)-Bicuculline: Practical Guide to GABAA Receptor Antagonis

  2026-05-19

  (+)-Bicuculline provides a means to selectively antagonize GABAA receptors and dissect inhibitory neurotransmission in neuroscience research. This compound is not suitable for diagnostic or clinical use and demands precise handling for reproducible results.

• Trelagliptin Succinate in Diabetes Research: Applied Protoco

  2026-05-19

  Trelagliptin succinate (SYR-472 succinate) offers unique workflow advantages for diabetes mellitus research, enabling once-weekly, long-acting DPP-4 inhibition. This article distills validated experimental protocols, novel cognitive endpoints, and troubleshooting strategies to maximize data quality across metabolic and inflammation models.

• Single-Base 5hmC Mapping Illuminates Rice Drought Epigenetic

  2026-05-18

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing how its genomic distribution and dynamic interplay with 5-methylcytosine (5mC) regulate gene expression during drought. The findings establish 5hmC as a context-dependent epigenetic mark, advancing research on plant stress adaptation and crop resilience.

• Enhanced mTOR Inhibitor Detection Using Drug-Sensitized Yeas

  2026-05-18

  Breen et al. introduce a yeast-based system with heightened sensitivity for identifying mechanistic target of rapamycin (mTOR) inhibitors, addressing the limitations of rapamycin and its analogs. This platform accelerates discovery of compounds with geroprotective and anti-cancer potential, and provides a robust negative control framework for non-TOR-targeted agents.

• A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover

  2026-05-17

  Breen et al. (2025) introduce a novel yeast-based assay system that dramatically increases sensitivity for detecting mTOR pathway inhibitors, facilitating rapid small-molecule screening. Their work clarifies that compounds like Canagliflozin do not cross-inhibit the mTOR pathway, guiding researchers toward more targeted, pathway-specific studies.

• Trelagliptin Succinate: Multidimensional Mechanisms in Diabe

  2026-05-16

  Explore the advanced biology of Trelagliptin succinate—a long-acting, selective DPP-4 inhibitor powering diabetes mellitus research and novel anti-inflammatory applications. Discover unique mechanistic insights and protocol strategies that set this compound apart.

• Anagliptin (SK-0403): DPP-4 Inhibition Meets Vascular Ion Ch

  2026-05-15

  Discover how Anagliptin (SK-0403) uniquely integrates DPP-4 inhibition with direct modulation of Kv channels and SERCA pumps, advancing research in diabetes and vascular physiology. This article uncovers the nuanced mechanisms and practical assay implications that set Anagliptin apart.

16475 records 1/1099 page Next 12345 下5页 Last page